Berry Lance A
Known title: DirectorCIK: 0001478716
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Treace Medical Shares Five-Year Bunion Study Results. Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.
Transaction History
| AORT | ▼ Sell | Open Market | 715 | $20K | 8/14/2026 | View on chart |
| TMCI | ▲ Buy | Grant | 30,000 | $0 | 5/19/2026 | View on chart |
| AORT | ▼ Sell | Open Market | 6,316 | $239K | 3/3/2026 | View on chart |
| AORT | ▼ Sell | Open Market | 5,178 | $197K | 3/2/2026 | View on chart |
| AORT | ▲ Buy | Grant | 40,874 | $0 | 3/2/2026 | View on chart |
| AORT | ▼ Sell | Open Market | 4,485 | $160K | 2/24/2026 | View on chart |
| AORT | ▲ Buy | Grant | 37,482 | $0 | 2/24/2026 | View on chart |
| AORT | ▼ Sell | Open Market | 4,981 | $187K | 2/23/2026 | View on chart |
| TMCI | ▲ Buy | Grant | 23,917 | $0 | 5/20/2025 | View on chart |
| AORT | ▼ Sell | Open Market | 4,909 | $122K | 3/6/2025 | View on chart |
| AORT | ▲ Buy | Grant | 48,100 | $0 | 3/6/2025 | View on chart |
| AORT | ▲ Buy | Grant | 34,435 | $0 | 2/28/2025 | View on chart |
| AORT | ▼ Sell | Open Market | 3,259 | $89K | 2/24/2025 | View on chart |
| TMCI | ▲ Buy | Grant | 15,091 | $0 | 5/21/2024 | View on chart |
| AORT | ▲ Buy | Grant | 37,000 | $0 | 2/23/2024 | View on chart |
| AORT | ▲ Buy | Grant | 42,064 | $750K | 12/6/2023 | View on chart |
| TMCI | ▲ Buy | Grant | 2,753 | $0 | 5/23/2023 | View on chart |
| TMCI | ▲ Buy | Grant | 2,832 | $0 | 10/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Artivion Q2 2026 Earnings Call Transcript Released
Artivion has released the transcript for its Q2 2026 earnings conference call, providing detailed insights into recent performance. The stock is currently trading near its 52-week low, reflecting a significant decline from its high. Analysts maintain a higher average price target, suggesting a gap between current market sentiment and long-term expectations.
Artivion Q2 2026 Earnings Call Transcript Released. Artivion has released the transcript for its Q2 2026 earnings conference call, providing detailed insights into recent performance. The stock is currently trading near its 52-week low, reflecting a significant decline from its high. Analysts maintain a higher average price target, suggesting a gap between current market sentiment and long-term expectations.